Literature DB >> 6255462

(R)-mevalonate excretion in human and rat urines.

R R Kopito, H Brunengraber.   

Abstract

(R)-Mevalonate was identified by radioenzymatic assay in human and rat urines. This was confirmed by spectrophotometric enzymatic assay of an ether extract of human urine. The average excretion rate of (R)-mevalonate in humans was 1.7 mumol/24 hr which corresponds to 29% of the glomerular filtration rate. In anesthetized rats the average rate of (R)-mevalonate excretion was 350 pmol/min, corresponding to 44% of the glomerular filtration rate. These rates were not affected by the sex of the subjects or animals. After bilateral nephrectomy, the concentration of (R)-mevalonate in rat serum increased within 2 hr to a new level that was 5 times that of sham-operated controls. Nephrectomized rats showed a decrease in their tolerance to an intravenous load of mevalonate. These data show that (R)-mevalonate is normally excreted in the urine of humans and rats. Urinary excretion of (R)-mevalonate should therefore be taken into account in in vivo studies on the metabolism of this compound.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255462      PMCID: PMC350145          DOI: 10.1073/pnas.77.10.5738

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  Stereospecificity of enzymic reactions involving mevalonic acid.

Authors:  R H CORNFORTH; K FLETCHER; H HELLIG; G POPJAK
Journal:  Nature       Date:  1960-03-26       Impact factor: 49.962

2.  Transfer of carbon atoms from mevalonate to n-fatty acids.

Authors:  J Edmond; G Popják
Journal:  J Biol Chem       Date:  1974-01-10       Impact factor: 5.157

3.  Mevalonate metabolism: role of kidneys.

Authors:  J Edmond; A M Fogelman; G Popják
Journal:  Science       Date:  1976-07-09       Impact factor: 47.728

4.  Sex differences in the sterol and nonsterol metabolism of mevalonate.

Authors:  M H Wiley; M M Howton; M D Siperstein
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

5.  Control of 3-hydroxy-3-methylglutaryl coenzyme A reductase by endogenously synthesized sterols in vitro and in vivo.

Authors:  P A Edwards; G Popják; A M Fogelman; J Edmond
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

6.  The in vitro metabolism of mevalonate by sterol and non-sterol pathways.

Authors:  M Righetti; M H Wiley; P A Murrill; M D Siperstein
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

7.  Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man.

Authors:  G Popják; G Boehm; T S Parker; J Edmond; P A Edwards; A M Fogelman
Journal:  J Lipid Res       Date:  1979-08       Impact factor: 5.922

8.  The quantitative role of the kidneys in the in vivo metabolism of mevalonate.

Authors:  M H Wiley; M M Howton; M D Siperstein
Journal:  J Biol Chem       Date:  1977-01-25       Impact factor: 5.157

9.  Studies of the in vivo metabolism of mevalonic acid in the normal rat.

Authors:  K H Hellstrom; M D Siperstein; L A Bricker; L J Luby
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

  9 in total
  4 in total

Review 1.  The contribution of the cholesterol biosynthetic pathway to intermediary metabolism and cell function.

Authors:  R Fears
Journal:  Biochem J       Date:  1981-10-01       Impact factor: 3.857

2.  Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man.

Authors:  T S Parker; D J McNamara; C Brown; O Garrigan; R Kolb; H Batwin; E H Ahrens
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

3.  Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeys.

Authors:  D J McNamara; E H Ahrens; T S Parker; K Morrissey
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

4.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.